{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:44:29Z","timestamp":1789771469182,"version":"4.0.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.xphs.2025.104023","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:07:30Z","timestamp":1760000850000},"page":"104023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Biowaiver monograph for immediate-release solid oral dosage forms: Empagliflozin"],"prefix":"10.1016","volume":"114","author":[{"given":"Reiji","family":"Negoya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuki","family":"Tsueoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuto","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertil","family":"Abrahamsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2519-1179","authenticated-orcid":false,"given":"Naseem A.","family":"Charoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Cristofoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Langguth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehul","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6875-3899","authenticated-orcid":false,"given":"Alan","family":"Parr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5274-4314","authenticated-orcid":false,"given":"James E.","family":"Polli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Dressman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2957-6287","authenticated-orcid":false,"given":"Atsushi","family":"Kambayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2025.104023_bib0001","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/IJGM.S100288","article-title":"Options for empagliflozin in combination therapy in type 2 diabetes mellitus","author":"Thompson","year":"2016","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.xphs.2025.104023_bib0002","unstructured":"Grand View Research. SGLT2 Inhibitors market size, share & trends analysis report by drug (Jardiance, Farxiga, Inpefa, Invokana), by indication (diabetes, cardiovascular), by distribution channel, by region, and segment forecasts, 2024 - 2030. Accessed March 14, 2025. https:\/\/www.grandviewresearch.com\/industry-analysis\/sglt2-inhibitors-market-report."},{"key":"10.1016\/j.xphs.2025.104023_bib0003","series-title":"In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation","article-title":"SUPAC-IR: immediate-release solid oral dosage forms: scale-up and post-approval changes: chemistry, manufacturing and controls","year":"1995"},{"issue":"2","key":"10.1016\/j.xphs.2025.104023_bib0008","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s13300-013-0030-2","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of Empagliflozin in patients with type 2 diabetes mellitus","volume":"4","author":"Heise","year":"2013","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.xphs.2025.104023_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcrysgro.2020.125489","article-title":"Manufacture and characterization of two distinct quasi-polymorphs of empagliflozin","volume":"534","author":"Kim","year":"2020","journal-title":"J Cryst Growth"},{"key":"10.1016\/j.xphs.2025.104023_bib0012","unstructured":"DRUGBANK Online. Empagliflozin. Accessed March 16, 2025. https:\/\/go.drugbank.com\/drugs\/DB09038."},{"issue":"8","key":"10.1016\/j.xphs.2025.104023_bib0015","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.clinthera.2015.06.003","article-title":"Pharmacokinetics and pharmacodynamics of twice daily and once daily regimens of empagliflozin in healthy subjects","volume":"37","author":"Macha","year":"2015","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.xphs.2025.104023_bib0016","doi-asserted-by":"crossref","first-page":"11","DOI":"10.22456\/2527-2616.112077","article-title":"Development and validation of a dissolution test for empagliflozin in film-coated tablets","volume":"5","author":"Manoel","year":"2021","journal-title":"Drug Anal Res"},{"issue":"3","key":"10.1016\/j.xphs.2025.104023_bib0017","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1021\/mp300410n","article-title":"Comparison of the permeability of metoprolol and labetalol in rat, mouse, and caco-2 cells: use as a reference standard for BCS classification","volume":"10","author":"Incecayir","year":"2013","journal-title":"Mol Pharm"},{"issue":"9","key":"10.1016\/j.xphs.2025.104023_bib0018","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1002\/jps.24258","article-title":"Direct in vivo human intestinal permeability (Peff) determined with different clinical perfusion and intubation methods","volume":"104","author":"Dahlgren","year":"2015","journal-title":"J Pharm Sci"},{"issue":"2","key":"10.1016\/j.xphs.2025.104023_bib0019","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/bdd.2025","article-title":"Caco-2 cells \u2013 expression, regulation and function of drug transporters compared with human jejunal tissue","volume":"38","author":"Br\u00fcck","year":"2017","journal-title":"Biopharm Drug Dispos"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925004770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925004770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T21:28:26Z","timestamp":1766525306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925004770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0022354925004770"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104023","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biowaiver monograph for immediate-release solid oral dosage forms: Empagliflozin","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.104023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104023"}}